by Raynovich Rod | Jun 9, 2017 | Biopharmaceuticals
ASCO Update: Many Stocks Rallied on the News Over the Past Month ASCO Rally is Holding but Fails to Break Through to New 2017 Highs The stock performance of most companies with ASCO news is summarized below.Biotechnology stocks are driven by clinical and deal news so...
by Raynovich Rod | Jun 5, 2017 | Biopharmaceuticals
June 5…ASCO Update: Incyte Puma and Roche A lot of the product news is already “baked into” stock prices but here is a brief summary of big movers today on clinical news updates. The bellwether XBI peaked at $71.72 today and is down 0.62% to $70.66....
by Raynovich Rod | May 31, 2017 | Biopharmaceuticals
6/1/17 Update at close…Biotechs Bounce off Bottom of 3 Month Trading Range IBB up 1.8% back above $290 after hitting 200 SMA bottom. XBI up 2.7% to $69.54 at SMA 50. XBI 2017 top is $72. XLV a safer play up over 1% to $76.91; above March highs and near 12 mo....
by Raynovich Rod | May 26, 2017 | Biopharmaceuticals
Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone? Technicals Matter Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ retained momentum with the ETF leader QQQ up 19% YTD pulling ahead of...
by Raynovich Rod | May 22, 2017 | Biopharmaceuticals
Biotech Trends: Immuno-Oncology Stocks Trending Strong Await ASCO Meeting on June 2 Prices as of Monday 11:45A with NASDAQ up 0.73% FBT $106.75 up 0.2%, IBB flat at $290.64, XBI at $69.33 up 0.3% Here is a selection of biotech trending stocks that have had...
by Raynovich Rod | May 16, 2017 | Biopharmaceuticals
Update-3…ASCO Movers Today 5/18: IBB up 1.28% to $292.27, XBI up 2% to $70. Nice follow through in biotech after a nasty day on 5/17 attributed to ASCO and a move away from the “Trump Trade” (industrials and materials). Mid-caps and small caps were...
by Raynovich Rod | May 8, 2017 | Biopharmaceuticals
May 8, 2017 Large Cap Biopharma Valuations After Q1 Earnings Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics: Best stock performance YTD are REGN up 15.3%, AMGN up...
by Raynovich Rod | May 1, 2017 | Biopharmaceuticals
Update: Big Down Day in Biotech XBI down 3% Article to follow: big movers down CELG,KITE, PBYI, TSRO, XLRN etc Update-1… 5/8/17…Biotech Sector Losing Momentum XBI down 4.3% over 5 days although still up 15.5% YTD. IBB very weak today down over 2%. NASDAQ...
by Raynovich Rod | Apr 25, 2017 | 2025 Rayno Biopharmaceuticals Portfolio
Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for...
by Raynovich Rod | Apr 15, 2017 | Biopharmaceuticals
Update at Close…April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at...
